Clinical bottom line
Novel biomarkers hold promise for predicting response to immunotherapy in autoimmune diseases, potentially enabling more personalized treatment strategies. Emerging data suggest that molecular signatures, extracellular vesicles, and immune cell surface markers may correlate with therapeutic outcomes. However, current evidence is largely preliminary and derived from small cohorts or extrapolated from oncology immunotherapy studies. Robust validation in autoimmune populations is needed before these biomarkers can be integrated into routine clinical decision-making.
What the evidence shows
Immunotherapy in autoimmune diseases, including biologics and cellular therapies, exhibits variable efficacy across patients. Identifying biomarkers predictive of response could optimize patient selection and improve outcomes. Several candidate biomarkers have emerged from recent research.
Extracellular vesicles (EVs), which carry proteins, lipids, and nucleic acids, have been implicated in immune regulation and beta cell health in type 1 diabetes (T1D). Jayabalan et al. (2026) highlight the clinical potential of EVs as non-invasive biomarkers reflecting disease activity and therapeutic response in T1D, though clinical validation remains pending.
Cell surface markers such as CD5, a regulator of immune tolerance, have multifunctional roles in immune disorders. Dong et al. (2025) discuss CD5’s involvement in modulating autoreactive lymphocytes and its potential as a biomarker for immunotherapy responsiveness, though direct clinical correlation data are limited.
In autoimmune encephalitis, cerebrospinal fluid (CSF) biomarkers have been studied for their predictive value regarding immunotherapy outcomes. Gao et al. (2025) report that specific CSF proteins correlate with treatment response, suggesting utility in guiding therapy intensity and duration.
While much biomarker research originates from cancer immunotherapy, insights are increasingly being translated to autoimmune contexts. Liu et al. (2025) performed a pan-cancer analysis identifying adrenomedullin (ADM) as a modulator of immune resistance and prognosis; such immune modulatory pathways may be relevant in autoimmune disease immunotherapy, warranting further exploration.
Editorial reviews emphasize the need for integrated biomarker panels combining genomic, proteomic, and cellular data to improve predictive accuracy (Huangfu et al., 2023). However, standardized assays and prospective validation studies are lacking.
Caveats and uncertainty
Most biomarker studies in autoimmune immunotherapy are exploratory, with small sample sizes and heterogeneous patient populations. Many candidate markers lack replication in independent cohorts or prospective validation.
Biomarker performance may vary by disease subtype, immunotherapy modality, and timing relative to treatment initiation. The dynamic nature of immune responses complicates static biomarker interpretation.
Extrapolation from oncology immunotherapy biomarkers to autoimmune diseases should be cautious due to differing pathophysiology and immune context.
Technical challenges include assay standardization, sensitivity, and specificity, as well as accessibility of sample types (e.g., CSF vs. blood).
Clinical utility remains unproven; no biomarker has yet demonstrated sufficient predictive power to guide immunotherapy decisions outside research settings.
How this may change practice
If validated, novel biomarkers could enable personalized immunotherapy by identifying patients most likely to benefit, minimizing exposure to ineffective treatments, and reducing adverse events.
Routine biomarker assessment might facilitate early treatment modification and improved monitoring of therapeutic efficacy.
Clinicians should stay abreast of emerging biomarker research and consider enrolling patients in biomarker-driven clinical trials.
Development of standardized, clinically feasible assays will be essential for translation into practice.
Ultimately, integrating biomarker data with clinical parameters and imaging may optimize individualized care in autoimmune immunotherapy.